The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma
Official Title: Phase 1b Multicenter Dose Escalation Study of Carfilzomib With Lenalidomide and Dexamethasone for Safety and Activity in Relapsed Multiple Myeloma
Study ID: NCT00603447
Brief Summary: To evaluate the safety and maximum tolerated dose (MTD) of carfilzomib in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Pacific Shores Medical Group, Long Beach, California, United States
Cedars Sinai Medical Center, Los Angeles, California, United States
University of California San Francisco, San Francisco, California, United States
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Northwestern University, Chicago, Illinois, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Cornell University, New York, New York, United States
Gabrail Cancer Center, Canton, Ohio, United States
MD Anderson Cancer Center, Houston, Texas, United States
Fred Hutch Cancer Research Center, Seattle, Washington, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Jewish General Hospital, Montreal, Quebec, Canada
Name: MD
Affiliation: Amgen
Role: STUDY_DIRECTOR